secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-107982
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track
------------------------------------------------------------------------------

- Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.
- Cash and equivalents $104.2M; expected to fund operations into 2026.
- Tarcocimab Phase 3 GLOW2 topline data expected Q1 2026; DAYBREAK (wet AMD) topline in Q3 2026.
- KSI-101 Phase 1b MESI data: half of patients ≥15 letter gain at Week 12; Phase 3 enrolling.
- Investor R&D Day on July 16, 2025 presented 12-week KSI-101 data and commercial strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/0000950170-25-107982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/kod-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer